Drug Type Autologous CAR-T |
Synonyms CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 1 | CN | 12 Dec 2024 | |
B-cell lymphoma refractory | Phase 1 | CN | 01 Apr 2024 |